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A B S T R A C T
Purpose
The identification of patients with metastatic triple-negative breast cancer (mTNBC) who are
expected to benefit from platinum-based chemotherapy is of interest. We conducted a single-arm
phase II clinical trial of single-agent platinum for mTNBC with biomarker correlates.
Patients and Methods
Patients with mTNBC received first- or second-line cisplatin (75 mg/m2) or carboplatin (area under
the concentration-time curve 6) by physician’s choice once every 3 weeks. Coprimary end points
were objective response rate (RR) and response prediction by p63/p73 gene expression.
Secondary and exploratory end points included toxicity assessment, RR in cisplatin versus
carboplatin, and RR in molecularly defined subgroups, including BRCA1/2 mutation carriers.
Results
Patients (N  86; 69 as first-line therapy) received cisplatin (n  43) or carboplatin (n  43).
RR was 25.6% (95% CI, 16.8% to 36%) and was numerically higher with cisplatin (32.6%)
than with carboplatin (18.7%). RR was 54.5% in patients with germline BRCA1/2 mutations
(n  11). In patients without BRCA1/2 mutations (n  66), exploratory analyses showed that
a BRCA-like genomic instability signature (n  32) discriminated responding and nonrespond-
ing tumors (mean homologous recombination deficiency–loss of heterozygosity/homologous
recombination deficiency–large-scale state transitions [HRD-LOH/HRD-LST] scores were
12.68 and 5.11, respectively), whereas predefined analysis by p63/p73 expression status (n 
61), p53 and PIK3CA mutation status (n  53), or PAM50 gene expression subtype (n  55)
did not. Five of the six long-term responders alive at a median of 4.5 years lacked germline
BRCA1/2 mutations, and two of them had increased tumor HRD-LOH/HRD-LST scores.
Conclusion
Platinum agents are active in mTNBC, especially in patients with germline BRCA1/2 mutations. A
measure of tumor DNA repair function may identify patients without mutations who could benefit
from platinum therapy agents. Prospective controlled confirmatory trials are warranted.
J Clin Oncol 33:1902-1909. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Triple-negative breast cancer (TNBC), defined clin-
ically as lacking estrogen receptor (ER) and proges-
terone receptor (PgR) expression and human
epidermal growth factor receptor 2 (HER2) gene
amplification, represents up to 20% of all breast
cancers and is associated with a more aggressive
clinical course in the metastatic setting compared
with other breast cancer subtypes.1,2 Most TNBCs
share common histologic and molecular features,
including high grade, frequent TP53 mutation, and
frequent expression of a so-called basal-like gene
expression signature on hierarchical clustering anal-
ysis.3 Nonetheless, TNBC is a heterogeneous disease
entity and is likely to represent multiple clinically
and biologically distinct subgroups that are not yet
clearly defined.4,5
Approximately 80% of breast cancers arising in
BRCA1 mutation carriers are TNBCs, and these tu-
mors are characterized by a defect in DNA double-
strand break repair which is thought to render them
particularly sensitive to interstrand cross-linking
agents, including platinum analogs.6 Accordingly,
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high pathologic complete response (pCR) rates have been observed
among BRCA1 carriers treated with cisplatin in the preoperative set-
ting,7,8 and high response rates (RRs) were also observed among one
small cohort of BRCA1 carriers treated with cisplatin in the metastatic
setting.9 Evidence suggests that a group of sporadic TNBCs may also
exhibit platinum sensitivity, possibly associated with a BRCA-like
phenotype in a subset of patients.10,11 Collectively, these findings have
suggested that platinum-based chemotherapy may be particularly ef-
fective for TNBC.
Enthusiasm for platinum treatment of TNBC is tempered by
both retrospective analyses and small prospective studies that have
yielded a mixed picture of whether patients with TNBC in general
derive benefit from platinum.12 In the metastatic setting, reported RRs
vary from 10% to more than 40% in prospective studies that included
single-agent cisplatin or carboplatin.12,13 Such differences may reflect
subtle differences in patient selection in these trials, but they also speak
to the need to identify subsets of patients with TNBCs who are likely to
benefit from platinum-based therapy. To address this need, we con-
ducted a multicenter phase II clinical trial (TBCRC009: Platinum for
Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73
as a Biomarker of Response) of cisplatin or carboplatin treatment in
the first- or second-line setting for metastatic TNBC (mTNBC). We
interrogated the BRCA1/2 pathway through germline BRCA1/2 se-
quencing and tumor somatic genomic analysis, and we evaluated




Eligible patients had metastatic or locally recurrent unresectable TNBC.
ER, PgR, and HER2 status were determined locally and were not centrally
reviewed. Paraffin blocks or unstained slides of tumor were required from all
patients for correlative studies. Additional eligibility criteria included measur-
able disease according to RECIST (Response Evaluation Criteria in Solid
Tumors) 1.0, Eastern Cooperative Oncology Group performance status  2,
life expectancy more than 12 weeks, normal organ and bone marrow function,
no more than one prior cytotoxic chemotherapy for metastatic disease, no
prior cisplatin or carboplatin therapy, and no active brain metastases. All
patients provided written informed consent, and the study was approved by
the institutional review boards at each participating site.
Study Design and Treatment Plan
This open-label, single-arm, two-stage phase II clinical trial was con-
ducted at eight Translational Breast Cancer Research Consortium centers in
the United States. Eligible patients were assigned at the discretion of their
treating physician to receive either cisplatin 75 mg/m2 (cohort 1) or carbopla-
tin at area under the time-concentration curve 6 (cohort 2) once every 3 weeks.
Accrual to each cohort was limited to ensure an equal number of patients in
each cohort. At the discretion of the treating physician after cycle 1, growth
factors were permitted, and treatment cycles could be extended to 4 weeks.
Oral magnesium and potassium supplementation was encouraged. Tumor
response was assessed locally by computed tomography according to
RECIST 1.0 every two cycles for the first four cycles and every three cycles
thereafter. Patients were treated until disease progression, unacceptable
toxicity, or withdrawal of consent. Treatment delay up to 3 weeks and two
dose reductions were permitted. Blood was collected from all patients for
germline BRCA1/2 analysis. Patients were observed annually until death or
the October 2013 data cutoff.
Further details of all correlative studies are described in the Data Supple-
ment. All correlative studies were performed blinded to clinical end points.
The study was designed in accordance with REMARK biomarker guidelines,
recognizing that homologous recombination deficiency (HRD) analysis was
developed subsequent to study initiation.14
RESULTS
Patient Characteristics
Patient demographics and baseline characteristics are provided
in Table 1. Between June 2007 and October 2010, 86 patients were
accrued. The original study design called for 41 patients to be treated
with first-line cisplatin. After a total of 15 patients were accrued to
first-line cisplatin therapy, a protocol amendment was activated on
July 28, 2008, that increased the planned accrual to 82 patients and
expanded protocol therapy to include carboplatin or cisplatin accord-
ing to physician’s choice as first- or second-line therapy. A total of 43
patients were accrued to each treatment cohort. The majority of pa-
tients (86%) had received prior adjuvant or neoadjuvant therapy,
most with an anthracycline (74%) and taxane (78%). Patients had a
median of two sites of disease, and 45% of patients had at least three





 40 13 15
40-65 63 73
 65 10 12
Race/ethnicity
White 69 80
African American 7 8
Asian 4 5
 One or other 6 7




Not reported 6 7
Sites of metastases

















Cisplatin (cohort 1) 43 50
Carboplatin (cohort 2) 43 50
Abbreviation: ECOG PS, Eastern Cooperative Oncology Group perfor-
mance status.
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sites. Lymph nodes were the most common metastatic site (63%),
followed by lungs (51%), liver (29%), bone (29%), and skin (19%).
Efficacy
The overall RR was 25.6%, including three complete responses
(CRs) and 19 partial responses (Table 2). An additional four patients
(4.7%) had stable disease for more than 6 months. The median num-
ber of cycles delivered was four (range, one to 23 cycles), and 12
patients (14%) received more than 10 cycles of therapy. Preplanned
exploratory subgroup analysis included determination of RR by line of
therapy and by chemotherapy agent. The RR was 29% with first-line
therapy and 11.8% with second-line therapy (P  .22). Cisplatin
therapy had an RR of 32.6% compared with 18.6% for carboplatin
(P  .22). At a median follow-up of 49.9 months, 75 patients had died;
the median progression-free survival (PFS) was 2.9 months and over-
all survival (OS) was 11 months (Figs 1A and 1C). There was, however,
considerable clinical heterogeneity; by the time of the first tumor
assessment at 6 weeks, 33% of patients had progressed, but 25% of
patients had a PFS beyond 6 months.
Toxicity
Single-agent cisplatin or carboplatin had generally mild toxicity,
with fatigue, nausea, electrolyte abnormalities, and hematologic tox-
icity among the most common (Data Supplement). Most events were
similar between the two cohorts. However, thrombocytopenia was
more common with carboplatin (47% v 19%). Anemia (81% v 65%),
neutropenia (49% v 35%), hypomagnesemia (42% v 23%), tinnitus
(37% v 0%), and anorexia (26% v 9%) were more common with
cisplatin. Grade 3 and 4 adverse events were rare and generally similar
between cisplatin and carboplatin. Grade 3 and 4 adverse events oc-
curring in at least 5% of all patients included fatigue, neutropenia,
dyspnea, anemia, hyperglycemia, and hyponatremia (Data Supple-
ment). No treatment-related deaths were reported. Ten patients dis-
continued study treatment for treatment-related toxicity, including
neuropathy (5), fatigue (4), allergic reaction (3; all with carboplatin),
renal dysfunction (2), transaminitis (1), and ototoxicity (1).
p63/p73 Ratio and Response
A coprimary end point of this study was prediction of treatment
response through analysis of messenger RNA expression for the two
p53-related genes p63 (TP63) and p73 (TP73). Preclinical data suggests
that the Np63 isoform functions as a survival factor in TNBC and
other cancers, in part by inhibiting the proapoptotic p73 isoform
TAp73.15 Applying a prespecified Np63/TAp73 ratio cutoff more
than 2 and by using the same methodology as in a prior study,8 we did
not observe a significant association of this ratio with RR or clinical
benefit among 61 evaluable tumors (Data Supplement, and data not
shown). However, we did note the association of this ratio with clinical
benefit among the small group of patients (n  7) who presented with
de novo metastatic disease and therefore had not received prior ther-
apy (Data Supplement).
BRCA1/2 Status and Response
The status of germline BRCA1 and BRCA2 was assessable in 77 of
86 patients. Eleven patients with germline BRCA1/2 deleterious mu-
tations were identified (Table 2) and, as anticipated, most harbored
BRCA1 mutations (nine of 11). These patients roughly matched the
cohort as a whole in terms of prior adjuvant therapy (10 of 11) and
first-line therapy (eight of 11), although a higher fraction received
cisplatin than carboplatin (seven of 11). Individuals with BRCA1/2
mutations were more likely to achieve a response than those without
mutations (54.5% v 19.7%; 95% CI, 23.4% to 83.3% v 10.9% to
31.3%; P  .022; Table 2). Notably, however, responses in these
BRCA1/2carrierswerenotdurable,noneachievedaCR,andPFSwasnot
significantly different between carriers and noncarriers (median 3.3 v 2.8
months; P  .92; Fig 1B). No significant difference in OS was observed
betweencarriersandnoncarriers(median13.7v10.9months;P .58;Fig
1D). Among all BRCA1/2 carriers, the two BRCA2 carriers demonstrated
the longest PFS and the longest OS (data not shown).
To extend the characterization of the BRCA1/2 pathway, we
interrogated available tumors from these patients (n32) for somatic
BRCA1/2 mutations, and in addition, we used two assays that mea-
sured discrete patterns of BRCA-associated genomic instability, orig-
inally derived through comparison of BRCA1/2 versus nonmutant
tumors.10,11 The HRD large-scale state transition (HRD-LST) assay
identifies chromosome breaks (translocations, inversions, or dele-
tions) resulting in adjacent segments of at least 10 Mb,10 whereas the
HRD loss of heterozygosity (HRD-LOH) assay identifies regions
showing LOH of intermediate size.11 As predicted, values for these two
assays among all the tumors were significantly correlated (Data Sup-
plement). Also as expected, significantly higher values for HRD-LST
and for the mean of HRD-LST plus HRD-LOH were observed in
tumors from patients with BRCA1/2 mutations (including one iden-
tified somatic BRCA1 mutation) than in tumors from noncarriers
(carrier v noncarrier mean HRD-LST plus HRD-LOH, 13.81 v 6.52; P
 .0089; Fig 2A). Most notably, tumors from patients who responded
to platinum but lacked germline mutations exhibited higher values
for both of the assays and a statistically significant difference for the
combined values (response v no response mean HRD-LST plus
HRD-LOH, 12.68 v 5.11; P  .0318; Fig 2B). Greater correlation
Table 2. Treatment Response and Exploratory Subgroup Analysis
RECIST Response
No. of
Patients % 95% CI Response
Overall RR (N  86) 22 25.6 16.8 to 36.1
CR 3 3.5
PR 19 22.1





Mutated (n  11) 6 54.5 23.4 to 83.3 6 PR
Wild type (n  66) 13 19.7 10.9 to 31.3 10 PR, 3 CR
Unknown (n  9) 3 33.3 7.5 to 70.1 3 PR
Cisplatin (n  43) 14 32.6 19.1 to 48.5
First line (n  34) 12 35.3 10 PR, 2 CR
Second line (n  9) 2 22.2 2 PR
Carboplatin (n  43) 8 18.6 8.4 to 33.4
First line (n  35) 8 22.9 7 PR, 1 CR
Second line (n  8) 0 0
First line (n  69) 20 29.0
Second line (n  17) 2 11.8
Abbreviations: CR, complete response; NE, not evaluable; PD, progressive
disease; PR, partial response; RR, response rate; SD, stable disease.
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was observed when patients with BRCA1 methylation were ex-
cluded from the BRCA1/2 wild-type analysis (Data Supplement)
and when response was analyzed as a continuous variable (Data
Supplement). Thus, responses of mTNBC to platinum therapy
in this trial are associated with either BRCA1/2 mutation or with
a tumor-specific genomic instability pattern characteristic of
BRCA1/2 deficiency.
Intrinsic Subtyping and Other Gene
Expression Signatures
We performed global gene expression profiling on available tumors
(n  55) to determine whether predefined molecular subsets of TNBC
benefited selectively from platinum. We first used the PAM50 gene set to
determine intrinsic subtypes among these TNBCs.16 In line with previous
studies that used similar methodology,3 62% (34 of 55) of these were
basal-like tumors. We observed a nonsignificant trend toward increased
RR in basal versus nonbasal TNBC (Fig 3 and Data Supplement), and no
differences in PFS or OS after platinum therapy (Data Supplement). We
next analyzed other previously described gene expression signatures re-
ported by Lehmann et al17 to subset TNBC (Fig 3).19 Although most were
not statistically associated with response to platinum in this cohort, the
luminal androgen receptor signature showed a significant negative asso-
ciationwithRR(Fig3andDataSupplement)butnoassociationwithPFS
or OS (data not shown).
Tumor Mutational and Genomic Analyses
The two genes most commonly subject to somatic mutation in
TNBC are the p53 tumor suppressor and the phosphatidylinositol
3-kinase (PI3K) catalytic subunit gene PIK3CA.3 Accordingly, we se-
quenced these genes in available tumors (n  53). As expected, p53
mutation was observed in approximately 60% of patients (36 of 52),
including the majority of BRCA1/2-associated and basal-like tumors (Fig
3 and data not shown). Although a somewhat larger proportion of pa-
tients with p53-mutant tumors responded to platinum (Data Supple-
ment), there was a consistent trend toward inferior OS for those with
p53-mutant versus wild-type tumors (Data Supplement).20 As expected,
relatively few tumors (nine of 53) harbored PIK3CA mutations, and all
but one of these patients experienced progressive disease as best response
(Fig 3 and Data Supplement).
Patients With Durable Responses and No
Active Disease
A small but notable subset of 6 long-term responding (LTR)
patients remain alive, progression free, and not receiving any therapy
at a median of more than 4 years after platinum treatment (Table 3).
Each of these patients achieved a partial response or CR to protocol
therapy; two of six eventually discontinued treatment because of tox-
icity and received no additional therapy, although the others went on
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Fig 1. (A) Progression-free survival and (C) overall survival estimates for all 86 enrolled patients. (B) Progression-free survival and (D) overall survival of BRCA1/2
mutation (MUT) carriers versus BRCA1/2 wild type (WT). Hazard ratios (HRs) and 95% CIs estimated by the Kaplan-Meier method. Patients were censored at last
follow-up or at time of change in therapy without progression.
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had received prior standard adjuvant chemotherapy before systemic
relapse, and all received platinum as first-line therapy. Sites of disease
varied (Table 3), but no patients had liver or bone involved. None of
the tested (five of six) LTR patients harbored germline BRCA1/2
mutations or rearrangements. However, the two tumors from LTR
patients available for HRD-LST/HRD-LOH analysis did show values
in line with those of other responding patients (Fig 2). None of the
other molecular analyses carried out in this cohort identified these
patients (Table 3).
DISCUSSION
This study was designed to test the efficacy of single-agent platinum-
based chemotherapy for mTNBC and to determine whether defined
genetic and molecular disease subsets exhibited significantly different
RRs. The observed RR of 25.6% was higher than the 10% RR seen by
using the same dose of cisplatin in a randomized phase II trial of
cisplatin plus cetuximab for mTNBC.21 Similarly, in the TBCRC
(Translational Breast Cancer Research Consortium) 001 trial for
mTNBC, an RR of 16% was observed with the combination of carbo-
platin and cetuximab after progression on cetuximab alone.22 Al-
though we observed a higher RR for cisplatin versus carboplatin in our
study, this difference must be interpreted with caution, given that our
study was a nonrandomized trial. Most likely, the explanation for the
differences in RR among these trials is multifactorial and reflects
diversity in patient populations or molecular subsets. For example,
given the significant difference we report in RRs between BRCA1/2
wild-type and mutation carriers, small differences in the number of
carriers (not reported in the other two studies) could have an impact
on the apparent overall RRs.
Compared with BRCA1/2 noncarriers, mutation carriers in our
study exhibited a significantly higher RR but no difference in PFS,
likely explained by relatively rapid subsequent disease progression in
carriers and the presence of a subset of noncarriers who exhibited
durable responses. Both the RR and PFS among carriers were substan-
tially lower than those observed in a small trial of single-agent cisplatin
in Poland that enrolled 20 BRCA1 carriers with metastatic breast





































































Fig 2. High homologous recombination deficiency–loss of heterozygosity (HRD-LOH) and homologous recombination deficiency–large-scale state transition
(HRD-LST) scores are associated with BRCA1/2 mutation and with platinum sensitivity. Primary tumor DNA was analyzed for two distinct genomic aberration patterns
(HRD-LST, HRD-LOH) as described in Results. Higher scores indicate increased aberrations. Horizontal lines show mean values  SEM. (A) BRCA1/2-mutant (MUT)
versus wild-type (WT) tumors. (B) Tumors of responding patients (complete response [CR] plus partial response [PR]) versus nonresponding patients (stable disease
[SD] plus progressive disease [PD]), excluding BRCA1/2-mutant tumors. Unpaired t test (Welch’s correction) was used to calculate P values. Gray circle indicates
germline BRCA1 mutation; blue circle indicates patient without germline or tumor somatic BRCA1/2 mutation, BRCA1 methylation, or long-term response; gold
diamond indicates somatic BRCA1 mutation; red diamond indicates germline BRCA2 mutation; gold triangle indicates BRCA1 promoter methylation; gold star indicates
long-term responder.
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patient-specific factors and the inclusion of patients with ER-positive
and/orPgR-positive tumors in theprior study(twoofwhichwereamong
four patients who exhibited prolonged responses). Nonetheless, both
studies support a selective sensitivity of BRCA1/2-associated tumors to
platinum-based therapy, even in the advanced setting.
Underscoring the functional link between the BRCA1/2 pathway
and platinum response in TNBC, we found that responses among
those who did not carry mutations were associated with the presence
of tumor genomic instability patterns characteristic of BRCA1/2-
mutant tumors. This finding is in line with other recent work report-
ing the ability of a genomic signature derived from BRCA1/2-mutant
tumors to predict clinical benefit from platinum-containing therapy
for breast cancer.23 We used two independent assays (HRD-LST and
HRD-LOH) that were both defined through analysis of BRCA1/2-
mutant (including BRCA1-methylated) versus wild-type tumors.10,11
Accordingly, we found that the results of the two assays were
highly correlated, and they identified the tumors of BRCA1/2
mutation carriers and those of responding patients without germ-
line BRCA1/2 mutations.
This is among the first studies to evaluate the HRD-LST and
HRD-LOH biomarkers in a metastatic population. Given the lack of
any predictive markers for chemotherapy responses in noncarriers
with TNBC, such assays could have major clinical impact. Our data
suggest that HRD-LOH and HRD-LST assays might be useful in
identifying a subset of patients who are unlikely to benefit from
platinum-based therapy; high HRD scores identified responders (high
sensitivity) but also some nonresponders (low specificity), whereas
low HRD scores were strongly associated with lack of response. Taken
together, our findings suggest that platinum sensitivity may be largely
or wholly a result of a defect in a BRCA1/2-related pathway for abnor-
mal DNA repair. Future randomized studies incorporating HRD
analysis will be needed to determine whether such biomarkers are
limited to predicting benefit specifically from platinum or more gen-









Fig 3. Summary of gene expression and mutational analysis. Each column represents one patient. Row 1: Progression-free survival (PFS) in days. Row 2: The four
RECIST response categories shown here are complete response (light blue), partial response (gray), stable disease (gold), and progressive disease (red). Row 3:
Germline BRCA1 (1) and BRCA2 (2); no mutation (blank). Row 4: Tumor p53 mutation analyses; no mutation (blank); missense mutation ([solid dot]);
nonsense/splice-site mutation ([solid star]). Row 5: Tumor PIK3CA mutation analyses; no mutation (blank); missense mutation ([solid dot]). Row 6: Np63:TAp73
messenger RNA expression ratio (ie, p63:p73)  2 ([solid dot]);  2 (blank).8 Row 7: PAM50 basal signature according to Nielson et al18; basal ([solid dot]); nonbasal
(blank). Row 8: Gene expression signatures derived from Lehmann et al17: unstable (dark blue), immunomodulatory (orange), mesenchymal stem-like (yellow), basal-like
1 (brown), basal-like 2 (light blue), luminal androgen receptor (black), and mesenchymal (green). (L) Long-term responders; (X) not available.
Table 3. Clinical, Genetic, and Tumor Molecular Features of Long-Term Responders



















28 WT N WT WT  2 58 Anthracycline-
taxane
Cisplatin PR Lymph nodes None





53 WT B WT Missense
mutation
 2 40 Anthracycline-
taxane
Cisplatin PR Lung None
69 X X X X X 41 Anthracycline-
taxane
Carboplatin PR Lung, lymph
nodes
Radiation








Abbreviations: B, basal (PAM50); CR, complete response; N, nonbasal; OS, overall survival; PR, partial response; WT, wild type; X, not available/not assessed.
To data lock in October 2013.
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A coprimary end point of the study was the ability of a gene
expression biomarker, the Np63:TAp73 ratio, to predict responses
to platinum-based therapy. In a prior study of preoperative cisplatin
treatment for TNBC, a prespecified cutoff ratio of Np63:TAp73
more than 2 was observed in 75% of tumors (3 of 4) with pathologic
CR (pCR) compared with 27% of tumors (three of 11) with poor
response.8 Although this end point was not met in this study, it is
relevant to note that patients with early-stage TNBC who obtain a pCR
(and thus for whom this biomarker might be predictive) are unlikely
to develop metastatic disease and therefore would be largely excluded
from our cohort. Collectively, these observations may serve as a cau-
tionary note for the application of biomarkers developed in the early-
stage setting to the metastatic population.
Established molecular biologic tumor features were of limited
value in predicting response to therapy in our small study. Most
notably, none of these established markers, including p53 and PIK3CA
mutations, basal subtype, or p63:p73 ratio identified the subset of
patients who exhibited prolonged responses and remain alive and
progression free to date. Five of these six patients were tested, and all
lacked germline BRCA1/2 mutations, although the two tumors from
this group tested did have HRD-LST and HRD-LOH scores in the
range of other responding patients (Fig 2). Notably, the ability of
patients who have relapsed after standard adjuvant chemotherapy
(four of the six LTRs) to achieve LTRs with platinum agents supports
the notion that platinum sensitivity may be a distinct form of chemo-
therapy sensitivity.
In summary, this work demonstrates the meaningful activity of
platinum-based chemotherapy for mTNBC. Our exploratory findings
in tumors lacking BRCA1/2 mutations suggest a genomic instability
pattern associated with defects in the BRCA1/2 pathway that may
predict response to therapy (platinum, in this study). Properly de-
signed prospective controlled trials that use analytically validated as-
says and predefined cutoffs are warranted to test the clinical utility of
measures of DNA repair status to predict responsiveness to platinum
and other DNA-damaging agents.
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GLOSSARY TERMS
basal-like: a gene expression pattern displayed by a subset of
breast cancers (approximately 15%-20%), usually in the setting
of a triple-negative phenotype, with increased expression of a
variety of cytokeratins and other markers such as epidermal
growth factor receptor typically found in the basilar epithelium
of the breast.
BRCA1: a tumor suppressor gene known to play a role in re-
pairing DNA breaks. Mutations in this gene are associated with
increased risks of developing breast or ovarian cancer.
BRCA2: a tumor suppressor gene whose protein product is
involved in repairing chromosomal damage. Although structur-
ally different from BRCA1, BRCA2 has cellular functions similar
to BRCA1. BRCA2 binds to RAD51 to fix DNA breaks caused by
irradiation and other environmental agents. Also known as the
breast cancer 2 early onset gene.
cisplatin: an inorganic platinum agent (cis-diamminedichloro-
platinum) with antineoplastic activity. Cisplatin forms highly re-
active, charged, platinum complexes, which bind to nucleophilic
groups such as GC-rich sites in DNA, inducing intrastrand and inter-
strand DNA cross-links as well as DNA-protein cross-links. These cross-
links result in apoptosis and cell growth inhibition. Carboplatin and
oxaliplatin are other members of this class.
homologous recombination: genetic recombination whereby
nucleotide sequences are exchanged between two similar or identical
strands of DNA to facilitate accurate repair of DNA double-strand
breaks.
RECIST (Response Evaluation Criteria in Solid
Tumors): a model proposed by the Response Evaluation Criteria
Group by which a combined assessment of all existing lesions, charac-
terized by target lesions (to be measured) and nontarget lesions, is used
to extrapolate an overall response to treatment.
triple-negative breast cancer (TNBC): breast tumors that are
negative for estrogen and progesterone receptor expression and that also
underexpress HER-neu.
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